The company forecast revenue next year will grow slightly versus this year, when excluding certain factors. “The uncertainty caused by COVID [is] mostly resolved,” its CFO said.

biopharmadive.com

Pfizer predicts stability, to Wall Street’s relief

Pfizer stock jumped early Tuesday after the pharma giant issued a mixed outlook for 2025. Revenue missed forecasts, while earnings beat some. The post Pfizer Stock Jumps On Mixed, But 'Marginally Encouraging,' 2025 Outlook appeared first on Investor's Business Daily.

All Sides

Media Bias/Fact Check

Investor's Business Daily

Pfizer Jumps On Mixed, But 'Marginally Encouraging,' Guidance

Pfizer (NYSE: PFE) shares rose nearly 3% to $25.98 in premarket trading on December 17 after the pharmaceutical giant released its 2025 financial guidance.  While the outlook painted a mixed picture, investor sentiment leaned positive, driven by an optimistic earnings forecast that signals progress in Pfizer’s ongoing turnaround efforts. At press time, Pfizer stock was trading at $26.30, marking a 2.7% gain for the day, with the monthly chart sh…

Finbold

Here's why Pfizer (PFE) stock is surging

The US pharmaceutical company Pfizer is cautious about the coming year. It is targeting sales of 61 billion to 64 billion US dollars in 2025,

Der US-Pharmakonzern Pfizer blickt verhalten auf das kommende Jahr. 2025 werde ein Umsatz von 61 Milliarden bis 64 Milliarden US-Dollar angepeilt,

Pfizer peilt für 2025 Umsatz auf Vorjahreshöhe an

nachrichten.at

Linz

Upper Austria

Austria

Pfizer targets sales at previous year's level for 2025

Pfizer's 2025 guidance is in line with market expectations, bringing some reassurance to investors after a turbulent period. The pharmaceutical giant's shares rose in over-the-counter trading after it released its future plans and financial outlook.

A Pfizer 2025-re vonatkozó előrejelzése megfelel a piaci várakozásoknak, ami némi megnyugvást hozott a befektetőknek egy turbulens időszak után. A gyógyszeripari óriás részvényei emelkedtek a tőzsdén kívüli kereskedésben, miután közzétette jövőbeli terveit és pénzügyi kilátásait.

Jó híreket közölt a Pfizer-vakcina gyártója

Portfolio.hu

The manufacturer of the Pfizer vaccine has announced good news

Amentum (NYSE:AMTM – Get Free Report) updated its FY25 earnings guidance on Monday. The company provided EPS guidance of $2.00-2.20 for the period, compared to the consensus EPS estimate of $1.41. The company issued revenue guidance of $13.80-14.20 billion, compared to the consensus revenue estimate of $13.98 billion. Amentum also updated its FY 2025 guidance […]

themarketsdaily.com

Amentum (NYSE:AMTM) Updates FY25 Earnings Guidance

Pfizer (NYSE:PFE – Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.800-3.000 for the period, compared to the consensus EPS estimate of 2.880. The company issued revenue guidance of $61.0 billion-$64.0 billion, compared to the consensus revenue estimate of $63.3 billion. Analysts […]

watchlistnews.com

Pfizer (NYSE:PFE) Issues FY 2025 Earnings Guidance

$PFE – PFIZER EXEC SAYS CO EXPECTS NO MATERIAL US POLICY CHANGES REGARDING VACCINES FROM THE INCOMING ADMINISTRATION IN 2025 -CONF CALL

franktrades.com

📰 $PFE – PFIZER EXEC SAYS CO EXPECTS NO MATERIAL US POLICY CHANGES REGARDING VACCINES FROM THE INCOMING ADMINISTRATION IN 2025 -CONF CALL

Pfizer is targeting a steady 2025, promising pipeline trims, cost cuts and smaller deals as it works to reassure investors about its path forward.
What it's not projecting is much growth. Its revenue next year ...

Endpoints News

Pfizer’s message to investors: The ship is steadying in 2025 (even if Washington is turbulent)

(Page 1) Chantilly, Va.-based Amentum Holdings, a reconfigured mega-player in the Department of Energy’s nuclear weapons complex, is poised to release its first

Pfizer predicts stability, to Wall Street’s relief

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics